- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about BRAXF
Recent news which mentions BRAXF
I Saw Trillions Of Atoms In My Hand Vibrating At A Certain Frequency, Says Zappy Zapolin Describing His First Psychedelics Experience
August 13, 2024
From Benzinga
Psychedelics Headlines: Predicting Readiness, Correcting The Hype, Good And Bad Drugs, Training Programs And More
March 01, 2024
From Benzinga
Podcast - Post-Frenzy Psychedelics Investing And Reclaiming The Right To Pursue Happiness With Zappy Zapolin: '2024 Is When It Goes Mainstream'
February 29, 2024
From Benzinga
Psyched: John Lennon Remembered, Clinical Trials For Service Members, Chrissy Teigen, Jon Feliciano And More
December 11, 2023
From Benzinga
Braxia Scientific's Q2 2024: Cash Burn Over But Income Low, What's Next For Psychedelics Company?
December 04, 2023
From Benzinga
Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
September 05, 2023
From Benzinga
Braxia Scientific Faces Challenges In Accessing Public Market Capital, Reports Q1 Loss
August 31, 2023
Tickers
BRAXF
From Benzinga
Psyched: Dubai Psychedelics Event, Key Receptor Discovered, Drew Barrymore, Oprah's Guest, Swiss MDMA & More
June 13, 2023
From Benzinga
BetterLife's Non-Hallucinogenic LSD's Clinical Studies, Braxia's Psychedelic Treatments Continue
June 09, 2023
From Benzinga
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
March 20, 2023
From Benzinga
From Benzinga
Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More
March 07, 2023
From Benzinga
Braxia Scientific's Q3 2023 Finances, Update On Upcoming Acquisition With Irwin Naturals
March 02, 2023
From Benzinga
Irwin Naturals Acquires Ketamine Clinic In Kentucky Adding $3M In Projected EBITDA
February 21, 2023
From Benzinga
Irwin Naturals Signs LOI To Acquire Braxia Scientific Expanding Its Network Of Mental Health Clinics
January 27, 2023
From Benzinga
From Benzinga
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
December 06, 2022
From Benzinga
Braxia Scientific Q2 2023 Financial Results: Health Clinic Ketamine Treatments Increases 34.5% YoY
December 01, 2022
Tickers
BRAXF
From Benzinga
Psyched: CA's Psychedelic-Assisted Treatments, Ketamine Therapy, Near-Death Experience And More
October 07, 2022
From Benzinga
Ketamine Therapy At Your Doorstep, Growing Number Of Clinics Offer This Treatment Option
October 05, 2022
From Benzinga
Great Psychedelics And Business Events Are Coming In Q4: Check Them Out Here
September 13, 2022
From Benzinga
4 Psychedelics Companies Post Financial Results: Learn How Field Trip, Wesana, Braxia and Irwin Naturals Performed
August 30, 2022
From Benzinga
Telehealth Market News: Braxia Scientific Enters Industry By Acquiring Ketamine Treatment Platform In Florida
August 03, 2022
Tickers
BRAXF
From Benzinga
Canadian Special Access Program Further Authorizes Novel Psychedelic Drugs For Emergency Treatments
June 16, 2022
From Benzinga
Braxia Opens New Clinic in Ontario, Facilitating Further Access To Ketamine And Psilocybin Treatments
June 15, 2022
Tickers
BRAXF
From Benzinga
From Benzinga
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
October 18, 2021
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.